News stories about Utah Medical Products (NASDAQ:UTMD) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Utah Medical Products earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 45.7511027481739 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, BidaskClub upgraded Utah Medical Products from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th.
Shares of UTMD stock traded up $1.90 during trading hours on Wednesday, hitting $96.85. The stock had a trading volume of 17,090 shares, compared to its average volume of 15,671. Utah Medical Products has a 12-month low of $58.50 and a 12-month high of $98.00. The company has a market cap of $348.25, a price-to-earnings ratio of 23.94 and a beta of 0.77.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 3rd. Shareholders of record on Friday, March 16th will be paid a dividend of $0.27 per share. The ex-dividend date is Thursday, March 15th. This represents a $1.08 annualized dividend and a yield of 1.12%. Utah Medical Products’s dividend payout ratio is 47.16%.
In other Utah Medical Products news, CEO Kevin L. Cornwell sold 1,100 shares of the firm’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $93.97, for a total transaction of $103,367.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin L. Cornwell sold 1,095 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $91.01, for a total value of $99,655.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,169 shares of company stock worth $1,466,903. Company insiders own 8.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Utah Medical Products (NASDAQ:UTMD) Receiving Somewhat Favorable News Coverage, Report Finds” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/2018/03/21/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-utah-medical-products-utmd-stock-price/1923596.html.
About Utah Medical Products
Utah Medical Products, Inc (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.